Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Ovid Therapeutics Inc
(NQ:
OVID
)
3.150
-0.050 (-1.56%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
113,127
Open
3.180
Bid (Size)
2.750 (1)
Ask (Size)
3.200 (1)
Prev. Close
3.200
Today's Range
3.110 - 3.216
52wk Range
2.570 - 4.139
Shares Outstanding
70,417,345
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Today 8:06 EDT
Via
Benzinga
Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
April 04, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Performance
YTD
-5.12%
-5.12%
1 Month
+1.94%
+1.94%
3 Month
-7.35%
-7.35%
6 Month
-12.74%
-12.74%
1 Year
-5.41%
-5.41%
More News
Read More
Over $2M Bet On NextNav? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
March 21, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Recap: Ovid Therapeutics Q4 Earnings
March 08, 2024
Via
Benzinga
Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results
March 08, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Earnings Perspective: Return On Capital Employed
May 22, 2023
Via
Benzinga
Ovid Therapeutics: Q1 Earnings Insights
May 05, 2023
Via
Benzinga
Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
February 28, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 06, 2024
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)
December 01, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates
November 03, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026
October 18, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit
October 10, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics to Host Investor Event - R&D Day on Monday, October 2, 2023
September 26, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
September 20, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics to Participate in Upcoming September Investor Conferences
August 30, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
3 Very Promising Penny Stocks That Are Flying Under the Radar
August 15, 2023
Via
InvestorPlace
Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates
August 04, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023
August 01, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy Officer
June 28, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Added to Russell 3000® Index
June 26, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2023
June 14, 2023
Via
Benzinga
Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates
May 05, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors
May 01, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Long-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study Presented by Takeda at American Academy of Neurology Annual Meeting
April 27, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.